Crossmark

Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis

Published Online: 2020-11-26

Published Print: 2021-06

Authors

Neuberger, Edward E. https://orcid.org/0000-0003-4037-0295
Abbass, Ibrahim M.

Jones, Eddie

Engmann, Natalie J.
Funding

Funding for this research was provided by:

Genentech
License Information

Text and Data Mining valid from 2020-11-26

Version of Record valid from 2020-11-26
More Information

Article History

Received: 23 September 2020

Accepted: 4 November 2020

First Online: 26 November 2020

Document is current